FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michael Untch

Research Profile

Disorders

Breast Neoplasms

Procedures

Chemicals & Drugs

Concepts & Ideas

Anatomy

Tumor Cells, Cultured

Geographic Areas

Germany

Co-author Network

Publications

TOP 3
Volker R Jacobs; Fritz Jaenicke; Eva Kantelhardt; Ronald E Kates; Manfred Schmitt; Christoph Thomssen; Michael Untch; Martina Vetter; Rachel Wuerstlein; Thorsten Fischer; Nadia Harbeck
Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer.
Stefan Gluck; Gunter von Minckwitz; Michael Untch
Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer.
Carsten Denkert; M Dietel; Jörn Hilfrich; T Kirchner; Ralf Kronenwett; Sibylle Loibl; Berit-Maria Müller; V Nekljudova; C Petry; C Roth; B V Sinn; C Solbach; A Staebler; Michael Untch; G Altmann; B Ataseven; Jan Budczies; S Darb-Esfahani; C von Törne; Gunter von Minckwitz
RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michael Untch (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Volker R Jacobs; Fritz Jaenicke; Eva Kantelhardt; Ronald E Kates; Manfred Schmitt; Christoph Thomssen; Michael Untch; Martina Vetter; Rachel Wuerstlein; Thorsten Fischer; Nadia Harbeck
Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer.
Breast cancer research and treatment 2013;138(3):839-50.
2013: Stefan Gluck; Gunter von Minckwitz; Michael Untch
Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer.
Breast (Edinburgh, Scotland) 2013;22(2):142-9.
2013: Carsten Denkert; M Dietel; Jörn Hilfrich; T Kirchner; Ralf Kronenwett; Sibylle Loibl; Berit-Maria Müller; V Nekljudova; C Petry; C Roth; B V Sinn; C Solbach; A Staebler; Michael Untch; G Altmann; B Ataseven; Jan Budczies; S Darb-Esfahani; C von Törne; Gunter von Minckwitz
RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013;24(3):632-9.
2013: Gunter von Minckwitz; Michael Untch; Sibylle Loibl
Update on neoadjuvant/preoperative therapy of breast cancer: experiences from the German Breast Group.
Current opinion in obstetrics & gynecology 2013;25(1):66-73.
2013: Maike de Wit; Carsten Bokemeyer; Hans-Peter Lipp; Regine Mayer-Steinacker; Petra Ortner; Markus Ruhnke; Jalid Sehouli; Michael Untch; Karin Jordan
Management of cytotoxic extravasation - ASORS expert opinion for diagnosis, prevention and treatment.
Onkologie 2013;36(3):127-35.
2013: Otto Metzger-Filho; Edith A Perez; Kathleen I Pritchard; Kamal S Saini; Sergio D Simon; Ian Smith; Michael Untch; Antonio C Wolff; Binghe Xu; Gursel Aktan; Jose Baselga; José Bines; Frances Boyle; Ian Bradbury; Evandro de Azambuja; Veerle Van Dooren; Christian Jackisch; Istvan Lang; Martine Piccart-Gebhart
Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience.
The oncologist 2013;18(2):134-40.
2012: Isabell Witzel; C Zu Eulenburg; Brigitte Rack; Christian Schem; S Schmatloch; Michael Untch; Gunter von Minckwitz; J Bischoff; Holger Eidtmann; P A Fasching; T Fehm; M Hauschild; Jens Huober; Y Issa-Nummer; Thomas Karn; F Khandan; C Liedtke; S Loibl; C Mau; Ivo Meinhold-Heerlein; Volkmar Müller
Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial.
British journal of cancer 2012;107(6):956-60.
2012: Nina Ditsch; A Hinke; Steffen Kahlert; Gottfried E Konecny; Miriam S Lenhard; B Löhrs; S Loibl; Bettina Toth; Ingo Bauerfeind; S Burghardt; Andrea Vodermaier; F Von Koch; G VON Minckwitz; Michael Untch
Dose-dense intensified sequential versus conventionally-dosed anthracycline and taxane-containing neoadjuvant therapy in patients with inflammatory breast cancer.
Anticancer research 2012;32(8):3539-45.
2012: Valentina Guarneri; Luca Marini; Antonino Musolino; Laura Orlando; Federico Piacentini; Alberto Ravaioli; Samanta Sarti; Patrizia Serra; Michael Untch; Fabrizio Artioli; Michela Bagnalasta; Giancarlo Bisagni; Corrado Boni; Alberto Bottini; Katia Cagossi; Luigi Cavanna; Roberto D'Amico; Antonio Frassoldati; Daniele Giulio Generali; Giovanni Giardina; Pierfranco Conte
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(16):1989-95.
2012: Gunter von Minckwitz; Keyur Mehta; Valentina Nekljudova; Michael Untch; Jens-Uwe Blohmer; Serban-Dan Costa; Carsten Denkert; Holger Eidtmann; Wolfgang Eiermann; Peter A Fasching; Bernd Gerber; Jörn Hilfrich; Jens Huober; Christian Jackisch; Manfred Kaufmann; Gottfried E Konecny; Sibylle Loibl
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(15):1796-804.
2012: Gunter von Minckwitz; Michael R Clemens; Silvia Darb-Esfahani; Kurt Diebold; Klaus Dietrich; Holger Eidtmann; Claus Hanusch; Stephan Henschen; Gerald Hoffmann; Frank Holms; Jens Huober; Marianne Just; Sibylle Loibl; Iris Schrader; Christine Solbach; Hans Tesch; Katharina Tiemann; Michael Untch; Carsten Denkert
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
Breast cancer research and treatment 2012;132(3):863-70.
2012: José Baselga; Ian Bradbury; Tsai-Wang Chang; Maria Coccia-Portugal; Evandro de Azambuja; Serena Di Cosimo; Phuong Dinh; Julien Domont; Holger Eidtmann; Karine Fauria; Richard D Gelber; Aron Goldhirsch; Henry Gómez; Zsolt Horváth; Georg Kunz; Guillermo Lerzo; Marketa Palacova; Martine J Piccart-Gebhart; Volodymyr Probachai; Lajos Pusztai; Vladimir Semiglazov; Joo Hyuk Sohn; Ling-Min Tseng; Michael Untch; Veerle Van Dooren; Gursel Aktan; Claudia Aura
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
Lancet 2012;379(9816):633-40.
2012: Michael Untch; Gunter von Minckwitz; Joachim Bischoff; Jens-Uwe Blohmer; Holger Eidtmann; Peter A Fasching; Bernd Gerber; Claus Hanusch; Jörn Hilfrich; Jens Huober; Christian Jackisch; Manfred Kaufmann; Rolf Kreienberg; Thorsten Kühn; Sibylle Loibl; Valentina Nekljudova; Mahdi Rezai; Dirk Strumberg; Hans Tesch
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.
The lancet oncology 2012;13(2):135-44.
2012: Michael Untch; Gottfried E Konecny; Sibylle Loibl; Gunter von Minckwitz
Neoadjuvant clinical trials for the treatment of primary breast cancer: the experience of the German study groups.
Current oncology reports 2012;14(1):27-34.
2012: Gunter von Minckwitz; Jens-Uwe Blohmer; Carsten Denkert; Holm Eggemann; Holger Eidtmann; Peter A Fasching; Tanja Fehm; Bernd Gerber; Claus Hanusch; Maik Hauschild; Jens Huober; Christian Jackisch; Kornelia Kittel; Rolf Kreienberg; Georg Kunz; Sibylle Loibl; Berit-Maria Müller; Valentina Nekljudova; Mahdi Rezai; Iris Schrader; Christine Solbach; Hans Tesch; Michael Untch
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
The New England journal of medicine 2012;366(4):299-309.
2012: Gunter von Minckwitz; Sibylle Loibl; Michael Untch
What is the current standard of care for anti-HER2 neoadjuvant therapy in breast cancer?
Oncology (Williston Park, N.Y.) 2012;26(1):20-6.
2011: Gunter von Minckwitz; Sibylle Loibl; Andrea Maisch; Michael Untch
Lessons from the neoadjuvant setting on how best to choose adjuvant therapies.
Breast (Edinburgh, Scotland) 2011;20 Suppl 3():S142-5.
2011: Michael Untch; Gunter von Minckwitz; Keyur M Mehta; Volkmar Müller; Elmar Stickeler; Thomas Beck; Oumar Camara; Andreas du Bois; Peter A Fasching; Werner Fett; Nadia Harbeck; Stephan Hasmüller; Cornelia Höss; Steffen Kahlert; Gottfried E Konecny; Rolf Kreienberg; Thorsten Kühn; Annette Lebeau; Sibylle Loibl
Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(25):3351-7.
2011: Michael Untch; H Urbaczyk; F Von Koch; G von Minckwitz; U Conrad; P A Fasching; W Fett; N Harbeck; S Hasmüller; Gottfried E Konecny; Christian Kurzeder; A Lebeau; M Lenhard; B Liedtke; Sibylle Loibl; Hans-Joachim Lück; V Müller; V Nekljudova; C Salat; M Schmidt; T Schuster; Elmar Stickeler
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer--results at the time of surgery.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(9):1988-98.
2011: Michael Untch; H Urbaczyk; G von Minckwitz; M W Beckmann; U Conrad; P A Fasching; W Fett; N Harbeck; S Hasmüller; Gottfried E Konecny; Christian Kurzeder; A Lebeau; M Lenhard; B Liedtke; Sibylle Loibl; Hans-Joachim Lück; V Müller; V Nekljudova; C Salat; M Schmidt; Elmar Stickeler
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosis.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(9):1999-2006.
2011: Dorit Di Gioia; Volker Heinemann; Steffen Kahlert; Thomas Koehnke; Dorothea Nagel; Ingo Bauerfeind; Michael Untch; Petra Stieber
Kinetics of CEA and CA15-3 correlate with treatment response in patients undergoing chemotherapy for metastatic breast cancer (MBC).
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2011;32(4):777-85.
2011: Luca Gianni; Urania Dafni; Richard D Gelber; Evandro Azambuja; Susanne Muehlbauer; Aron Goldhirsch; Michael Untch; Ian Smith; José Baselga; Christian Jackisch; David Cameron; Max Mano; José Luiz Pedrini; Andrea Veronesi; Cesar Mendiola; Anna Pluzanska; Vladimir Semiglazov; Eduard Vrdoljak; Michael J Eckart; Zhenzhou Shen; George Skiadopoulos; Marion Procter; Kathleen I Pritchard; Martine J Piccart-Gebhart; Richard Bell
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
The lancet oncology 2011;12(3):236-44.
2011: Michael Untch; Gunter von Minckwitz
Neoadjuvant chemotherapy: early response as a guide for further treatment: clinical, radiological, and biological.
Journal of the National Cancer Institute. Monographs 2011;2011(43):138-41.
2011: Andrea Vodermaier; Cornelia Caspari; Lisa Wang; Janna Koehm; Nina Ditsch; Michael Untch
How and for whom are decision aids effective? Long-term psychological outcome of a randomized controlled trial in women with newly diagnosed breast cancer.
Health psychology : official journal of the Division of Health Psychology, American Psychological Association 2011;30(1):12-9.
2011: Gunter von Minckwitz; Michael Untch; Eveline Nüesch; Sibylle Loibl; Manfred Kaufmann; Sherko Kümmel; Peter A Fasching; Wolfgang Eiermann; Jens-Uwe Blohmer; Serban-Dan Costa; Keyur Mehta; Jörn Hilfrich; Christian Jackisch; Bernd Gerber; Andreas du Bois; Jens Huober; Claus Hanusch; Gottfried Konecny; Werner Fett; Elmar Stickeler; Nadia Harbeck; Volkmar Müller; Peter Jüni
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials.
Breast cancer research and treatment 2011;125(1):145-56.
2010: Kerstin Hermelink; Helmut Küchenhoff; Michael Untch; Ingo Bauerfeind; Michael Patrick Lux; Markus Bühner; Juliane Manitz; Veronika Fensterer; Karin Münzel
Two different sides of 'chemobrain': determinants and nondeterminants of self-perceived cognitive dysfunction in a prospective, randomized, multicenter study.
Psycho-oncology 2010;19(12):1321-8.
2010: Isabell Witzel; Sibylle Loibl; Gunter von Minckwitz; Christoph Mundhenke; Jens Huober; Claus Hanusch; Stephan Henschen; Maik Hauschild; Tilmann Lantzsch; Hans Tesch; Kunibert Latos; Marianne Just; Jörn Hilfrich; Jana Barinoff; Christine Zu Eulenburg; Marc Roller; Michael Untch; Volkmar Müller
Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial.
Breast cancer research and treatment 2010;123(2):437-45.
2010: Annette Lebeau; Andreas Turzynski; Susanne Braun; Wera Behrhof; Barbara Fleige; Wolfgang D Schmitt; Tobias J Grob; Lia Burkhardt; Dieter Hölzel; Christian Jackisch; Christoph Thomssen; Volkmar Müller; Michael Untch
Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(20):3264-70.
2010: Volker Moebus; Christian Jackisch; Hans-Joachim Lueck; Andreas du Bois; Christoph Thomssen; Christian Kurbacher; Walther Kuhn; Ulrike Nitz; Andreas Schneeweiss; Jens Huober; Nadia Harbeck; Gunter von Minckwitz; Ingo B Runnebaum; Axel Hinke; Rolf Kreienberg; Gottfried E Konecny; Michael Untch
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(17):2874-80.
2010: Sabine Riethdorf; Volkmar Müller; Liling Zhang; Thomas Rau; Sibylle Loibl; Martina Komor; Marc Roller; Jens Huober; Tanja Fehm; Iris Schrader; Jörn Hilfrich; Frank Holms; Hans Tesch; Holger Eidtmann; Michael Untch; Gunter von Minckwitz; Klaus Pantel
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(9):2634-45.
2010: Gunter von Minckwitz; Mahdi Rezai; Sibylle Loibl; Peter A Fasching; Jens Huober; Hans Tesch; Ingo Bauerfeind; Jörn Hilfrich; Holger Eidtmann; Bernd Gerber; Claus Hanusch; Thorsten Kühn; Andreas du Bois; Jens-Uwe Blohmer; Christoph Thomssen; Serban Dan Costa; Christian Jackisch; Manfred Kaufmann; Keyur Mehta; Michael Untch
Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(12):2015-23.
2010: Michael Untch; Mahdi Rezai; Sibylle Loibl; Peter A Fasching; Jens Huober; Hans Tesch; Ingo Bauerfeind; Jörn Hilfrich; Holger Eidtmann; Bernd Gerber; Claus Hanusch; Thorsten Kühn; Andreas du Bois; Jens-Uwe Blohmer; Christoph Thomssen; Serban Dan Costa; Christian Jackisch; Manfred Kaufmann; Keyur Mehta; Gunter von Minckwitz
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(12):2024-31.
2010: Gottfried E Konecny; Giovanni Pauletti; Michael Untch; He-Jing Wang; Volker Möbus; Walther Kuhn; Christoph Thomssen; Nadia Harbeck; Ling Wang; Sophia Apple; Fritz Jänicke; Dennis J Slamon
Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer.
Breast cancer research and treatment 2010;120(2):481-9.
2010: Michael Untch; Michael Muscholl; Sergei Tjulandin; Walter Jonat; Hans-Gerd Meerpohl; Michail R Lichinitser; Alexey G Manikhas; Alexandra Coumbos; Rolf Kreienberg; Andreas du Bois; Nadia Harbeck; Christian Jackisch; Volkmar Müller; Matthias Pauschinger; Christoph Thomssen; Michaela Lehle; Olivier Catalani; Hans-Joachim Lück
First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(9):1473-80.
2010: Jörg Schwarz; R Tiling; S Avril-Sassen; Sven Mahner; A Lebeau; C Weber; M Schwaiger; Fritz Jänicke; Michael Untch; N Avril
Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer.
British journal of cancer 2010;102(1):35-41.
2010: Michael Untch; Christoph Thomssen
Clinical practice decisions in endocrine therapy.
Cancer investigation 2010;28 Suppl 1():4-13.
2009: Matti Aapro; Agustí Barnadas; Robert C Leonard; Maurizio Marangolo; Michael Untch; Lidia Ukarma; Hans-Ulrich Burger; Armin Scherhag; Bruno Osterwalder
What is the impact of antithrombotic therapy and risk factors on the frequency of thrombovascular events in patients with metastatic breast cancer receiving epoetin beta?
European journal of cancer (Oxford, England : 1990) 2009;45(17):2984-91.
2009: Michael Untch; Volker Möbus; Walther Kuhn; Bernd Rudolph Muck; Christoph Thomssen; Ingo Bauerfeind; Nadia Harbeck; Christoph Werner; Annette Lebeau; Andreas Schneeweiss; Stephen Kahlert; Franz von Koch; Karl Ulrich Petry; Diethelm Wallwiener; Rolf Kreienberg; Ute-Susann Albert; Hans-Joachim Lück; Axel Hinke; Fritz Jänicke; Gottfried E Konecny
Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(18):2938-45.
2009: Julia Bohlius; Kurt Schmidlin; Corinne Brillant; Guido Schwarzer; Sven Trelle; Jerome Seidenfeld; Marcel Zwahlen; Mike Clarke; Olaf Weingart; Sabine Kluge; Margaret Piper; Dirk Rades; David P Steensma; Benjamin Djulbegovic; Martin F Fey; ISABELLE RAY COQUARD; Mitchell Machtay; Volker Moebus; Gillian Thomas; Michael Untch; Martin Schumacher; Matthias Egger; Andreas Engert
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.
Lancet 2009;373(9674):1532-42.
2009: Andrea Vodermaier; Cornelia Caspari; J Koehm; Steffen Kahlert; Nina Ditsch; Michael Untch
Contextual factors in shared decision making: a randomised controlled trial in women with a strong suspicion of breast cancer.
British journal of cancer 2009;100(4):590-7.
2009: Jörg Schwarz; Michael Untch; Reinhold Tiling; Stefanie Sassen; Sven Mahner; Steffen Kahlert; Nadia Harbeck; Annette Lebeau; Winfried Brenner; M Schwaiger; Fritz Jaenicke; Norbert Avril
Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(4):535-41.
2009: Julia Bohlius; Kurt Schmidlin; Corinne Brillant; Guido Schwarzer; Sven Trelle; Jerome Seidenfeld; Marcel Zwahlen; Mike Clarke; Olaf Weingart; Sabine Kluge; Margaret Piper; Maryann Napoli; Dirk Rades; David Steensma; Benjamin Djulbegovic; Martin F Fey; ISABELLE RAY COQUARD; Volker Moebus; Gillian Thomas; Michael Untch; Martin Schumacher; Matthias Egger; Andreas Engert
Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data.
Cochrane database of systematic reviews (Online) 2009;(3):CD007303.
2009: Michael Untch; Gunter von Minckwitz
Recent advances in systemic therapy: advances in neoadjuvant (primary) systemic therapy with cytotoxic agents.
Breast cancer research : BCR 2009;11(2):203.
2009: Gordon Schwartz; Kevin S Hughes; Henry T Lynch; Carol J Fabian; Ian S Fentiman; Mark Robson; Susan M Domchek; Lynn C Hartmann; Roland Holland; David J Winchester; Benjamin O Anderson; Banu K Arun; Harry Bartelink; Philip Bernard; Bernardo Bonanni; Blake Cady; Krishna B Clough; Steven Feig; Sylvia H Heywang-Köbrunner; Anthony Howell; Claudine Isaacs; Daniel B Kopans; Robert E Mansel; Shahla Masood; Juan P Palazzo; PI Pressman; Lawrence J Solin; Michael Untch
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007.
The breast journal 2009;15(1):4-16.
2008: Michael Untch; Christian Jackisch
Exemestane in early breast cancer: a review.
Therapeutics and clinical risk management 2008;4(6):1295-304.
2008: Kerstin Hermelink; Volkmar Henschel; Michael Untch; Ingo Bauerfeind; Michael Patrick Lux; Karin Munzel
Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: results of a multicenter, prospective, longitudinal study.
Cancer 2008;113(9):2431-9.
2008: Miriam S Lenhard; Ingo Bauerfeind; Michael Untch
Breast cancer and pregnancy: challenges of chemotherapy.
Critical reviews in oncology/hematology 2008;67(3):196-203.
2008: Michael Untch; Richard D Gelber; C Jackisch; M Procter; J Baselga; R Bell; D Cameron; M Bari; I Smith; Brian Leyland-Jones; E de Azambuja; P Wermuth; R Khasanov; F Feng-Yi; C Constantin; J I Mayordomo; C-H Su; S-Y Yu; A Lluch; E Senkus-Konefka; C Price; F Haslbauer; T Suarez Sahui; V Srimuninnimit; M Colleoni; Alan Coates; M J Piccart-Gebhart; A Goldhirsch
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(6):1090-6.
2008: Miriam S Lenhard; Steffen Kahlert; Isabelle Himsl; Nina Ditsch; Michael Untch; Ingo Bauerfeind
Phyllodes tumour of the breast: clinical follow-up of 33 cases of this rare disease.
European journal of obstetrics, gynecology, and reproductive biology 2008;138(2):217-21.
2008: Matti Aapro; Robert C Leonard; Agustí Barnadas; Maurizio Marangolo; Michael Untch; Nikolaos Malamos; José I Mayordomo; Dietmar Reichert; José Luiz Pedrini; Lidia Ukarma; Armin Scherhag; Hans-Ulrich Burger
Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(4):592-8.
2007: Manfred Kaufmann; Gunter von Minckwitz; H D Bear; A Buzdar; P McGale; H Bonnefoi; M Colleoni; C Denkert; Wolfgang Eiermann; R Jackesz; Andreas Makris; W Miller; J-Y Pierga; Vladimir Semiglazov; Andreas Schneeweiss; Rainer Souchon; Vered Stearns; Michael Untch; Sibylle Loibl
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(12):1927-34.
2007: Dorit Laessig; Dorothea Nagel; Volker Heinemann; Michael Untch; Steffen Kahlert; Ingo Bauerfeind; Petra Stieber
Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients.
Anticancer research 2007;27(4A):1963-8.
2007: Ingo Bauerfeind; Steffen Kahlert; Isabelle Himsl; Yevgenia Sorokina; Ina M Ruehl; Annette Lebeau; Rainer Linke; Michael Untch; Klaus Friese
The risk of non-sentinel metastases in primary breast cancer.
Anticancer research 2007;27(4A):1929-32.
2007: Peter Schmid; Michael Untch; Valentin Kossé; Grigorij Bondar; Leonid Vassiljev; Valerie Tarutinov; Ute Lehmann; Lutz Maubach; Juergen Meurer; Diethelm Wallwiener; Kurt Possinger
Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(18):2509-15.
2007: Kerstin Hermelink; Michael Untch; Michael P Lux; Rolf Kreienberg; Thomas Beck; Ingo Bauerfeind; Karin Münzel
Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study.
Cancer 2007;109(9):1905-13.
2007: M Hunz; Alexander Jetter; Mathias Warm; E Pantke; M Tuscher; Georg Hempel; Ulrich Jaehde; Michael Untch; Christian M Kurbacher; Uwe Fuhr
Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer.
Clinical pharmacology and therapeutics 2007;81(5):659-68.
2007: Michael Untch; Christian Jackisch
Optimal treatment strategies in hormone-responsive early breast cancer: the role of aromatase inhibitors.
Onkologie 2007;30(1-2):55-64.
2007: Ian Smith; Marion Procter; Richard D Gelber; Sébastien Guillaume; Andrea Feyereislova; Mitch Dowsett; Aron Goldhirsch; Michael Untch; Gabriella Mariani; José Baselga; Manfred Kaufmann; David Cameron; Richard Bell; Jonas Bergh; Robert Coleman; Andrew Wardley; Nadia Harbeck; Roberto I Lopez; Peter Mallmann; Karen Gelmon; Nicholas Wilcken; Erik Wist; Pedro Sánchez-Rovira; Martine J Piccart-Gebhart
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.
Lancet 2007;369(9555):29-36.
2006: Miriam S Lenhard; Thorsten Johnson; Isabelle Himsl; Nina Ditsch; Sandra Rueckert; Klaus Friese; Michael Untch
Obstetrical and gynecological writing and publishing in Europe.
European journal of obstetrics, gynecology, and reproductive biology 2006;129(2):119-23.
2006: Andrea Vodermaier; Ingo Bauerfeind; Michael Untch; Caroline Nestle-Krämling
[Prophylactic mastectomy in women at high risk for breast and ovarian cancer: qualitative analysis of the decision making process and long-term satisfaction of two women carrying a BRCA1-mutation].
Psychotherapie, Psychosomatik, medizinische Psychologie 2006;56(9-10):351-61.
2006: Timo Hakulinen; Michael Untch; Richard Farmer
What is new in breast cancer? The expanding role of aromatase inhibitors.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2006;22 Suppl 2():1-13.
2006: Bernd Frank; Kari Hemminki; Barbara Wappenschmidt; Rüdiger Klaes; Alfons Meindl; Rita K Schmutzler; Peter Bugert; Michael Untch; Claus R Bartram; Barbara Burwinkel
Variable number of tandem repeats polymorphism in the SMYD3 promoter region and the risk of familial breast cancer.
International journal of cancer. Journal international du cancer 2006;118(11):2917-8.
2006: Philipp Kiewe; Stephan Hasmüller; Steffen Kahlert; Maja Heinrigs; Brigitte Rack; Alexander Marmé; Agnieszka Korfel; Michael Jäger; Horst Lindhofer; Harald Sommer; Eckhard Thiel; Michael Untch
Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(10):3085-91.
2006: Bernd Frank; Kari Hemminki; Alfons Meindl; Barbara Wappenschmidt; Rüdiger Klaes; Rita K Schmutzler; Michael Untch; Peter Bugert; Claus R Bartram; Barbara Burwinkel
Association of the ARLTS1 Cys148Arg variant with familial breast cancer risk.
International journal of cancer. Journal international du cancer 2006;118(10):2505-8.
2006: Manfred Kaufmann; Gabriel N Hortobagyi; Aron Goldhirsch; Suzy Scholl; Andreas Makris; Pinuccia Valagussa; Jens-Uwe Blohmer; Wolfgang Eiermann; Raimund Jackesz; Walter Jonat; Annette Lebeau; Sibylle Loibl; William Miller; Sigfried Seeber; Vladimir Semiglazov; Roy Smith; Rainer Souchon; Vered Stearns; Michael Untch; Gunter von Minckwitz
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(12):1940-9.
2006: Annika Vaclavicek; Kari Hemminki; Claus R Bartram; Kerstin Wagner; Barbara Wappenschmidt; Alfons Meindl; Rita K Schmutzler; Rüdiger Klaes; Michael Untch; Barbara Burwinkel; Asta Försti
Association of prolactin and its receptor gene regions with familial breast cancer.
The Journal of clinical endocrinology and metabolism 2006;91(4):1513-9.
2006: S M Lenhard; Michael Untch; Isabelle Himsl; Nina Ditsch; Iris Bittmann; Klaus Friese; Ingo Bauerfeind
The high-grade endometrial sarcoma: a rare entity.
Archives of gynecology and obstetrics 2006;274(1):56-9.
2006: Hans-Joachim Stemmler; Steffen Kahlert; W Siekiera; Michael Untch; B Heinrich; Volker Heinemann
Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer.
Breast (Edinburgh, Scotland) 2006;15(2):219-25.
2006: Bernd Frank; Kari Hemminki; Barbara Wappenschmidt; Alfons Meindl; Rüdiger Klaes; Rita K Schmutzler; Peter Bugert; Michael Untch; Claus R Bartram; Barbara Burwinkel
Association of the CASP10 V410I variant with reduced familial breast cancer risk and interaction with the CASP8 D302H variant.
Carcinogenesis 2006;27(3):606-9.
2006: Gottfried E Konecny; Mark D Pegram; Natarajan Venkatesan; Richard Finn; Guorong Yang; Martina Rahmeh; Michael Untch; David W Rusnak; Glenn Spehar; Robert J Mullin; Barry R Keith; Tona M Gilmer; Mark Berger; Karl C Podratz; Dennis J Slamon
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
Cancer research 2006;66(3):1630-9.
2006: Stefan Wilkening; Justo Lorenzo Bermejo; Barbara Burwinkel; Rüdiger Klaes; Claus R Bartram; Alfons Meindl; Peter Bugert; Rita K Schmutzler; Barbara Wappenschmidt; Michael Untch; Kari Hemminki; Asta Försti
The single nucleotide polymorphism IVS1+309 in mouse double minute 2 does not affect risk of familial breast cancer.
Cancer research 2006;66(2):646-8.
2005: Hans-Joachim Stemmler; Steffen Kahlert; Wolfgang Siekiera; Michael Untch; Bernhard Heinrich; Volker Heinemann
Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC).
Onkologie 2005;28(11):582-6.
2005: Bernd Frank; Kari Hemminki; Kalai Selvi Shanmugam; Alfons Meindl; Rüdiger Klaes; Rita K Schmutzler; Barbara Wappenschmidt; Michael Untch; Peter Bugert; Claus R Bartram; Barbara Burwinkel
Association of death receptor 4 haplotype 626C-683C with an increased breast cancer risk.
Carcinogenesis 2005;26(11):1975-7.
2005: Hans-Joachim Stemmler; Christoph Salat; Horst Lindhofer; H Menzel; Michael Untch; Steffen Kahlert; Gottfried E Konecny; Hansjörg Sauer; Georg Ledderose; Volker Heinemann; Hans-Jochem Kolb
Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot study.
Anticancer research 2005;25(4):3047-54.
2005: S Rueckert; I Ruehl; Steffen Kahlert; Gottfried E Konecny; Michael Untch
A monoclonal antibody as an effective therapeutic agent in breast cancer: trastuzumab.
Expert opinion on biological therapy 2005;5(6):853-66.
2005: R C Leonard; Michael Untch; F Von Koch
Management of anaemia in patients with breast cancer: role of epoetin.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(5):817-24.
2005: Harald Sittek; A Wieser; M Kessler; Stefanie Britsch; C Vick; Michael Untch; Maximilian Reiser
[Sonographically guided, minimally invasive biopsy of uncertain mammary lesions. Clinical experience with a new biopsy system].
Der Radiologe 2005;45(3):269-77.
2005: Harald Sittek; N Heske; M Kessler; Stefanie Britsch; C Vick; Michael Untch; Maximilian Reiser
[O-twist marker for post-interventional marking in imaging of suspected breast lesions].
Der Radiologe 2005;45(3):223-9.
2005: Reinhold Tiling; Mareike Kessler; Michael Untch; Harald Sommer; Rainer Linke; Klaus Hahn
Initial evaluation of breast cancer using Tc-99m sestamibi scintimammography.
European journal of radiology 2005;53(2):206-12.
2005: Thorsten Kuehn; Andreas Bembenek; Thomas Decker; Dieter L Munz; Marie-Luise Sautter-Bihl; Michael Untch; Diethelm Wallwiener
A concept for the clinical implementation of sentinel lymph node biopsy in patients with breast carcinoma with special regard to quality assurance.
Cancer 2005;103(3):451-61.
2004: Michael Untch; Isabelle Himsl; Steffen Kahlert; Hans-Joachim Lueck; Holger Eidtmann; Andreas du Bois; Hans-Gerd Meerpohl; Christoph Thomssen; Nadia Harbeck; Christian Jackisch; R Kreienberg; G Emons; D Wallwiener; W Wiese; G Schaller; Walther Kuhn; Michael Muscholl; M Pauschinger; B Langer
Anthracycline and trastuzumab in breast cancer treatment.
Oncology (Williston Park, N.Y.) 2004;18(14 Suppl 14):59-64.
2004: Richard Bell; Shail Verma; Michael Untch; David Cameron; Ian Smith
Maximizing clinical benefit with trastuzumab.
Seminars in oncology 2004;31(5 Suppl 10):35-44.
2004: Gottfried E Konecny; Christoph Thomssen; Hans-Joachim Lück; Michael Untch; He-Jing Wang; Walther Kuhn; Holger Eidtmann; Andreas du Bois; Sigrid Olbricht; Dieter Steinfeld; Volker Möbus; Gunter von Minckwitz; Sugandha Dandekar; Lillian Ramos; Giovanni Pauletti; Mark D Pegram; Fritz Jänicke; Dennis J Slamon
Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.
Journal of the National Cancer Institute 2004;96(15):1141-51.
2004: Michael R Dufault; Beate Betz; Barbara Wappenschmidt; Wera Hofmann; Katrin Bandick; Astrid Golla; Andrea Pietschmann; Caroline Nestle-Krämling; Kerstin Rhiem; Christine Hüttner; Celia von Lindern; Peter Dall; Marion Kiechle; Michael Untch; Walter Jonat; Alfons Meindl; Siegfried Scherneck; Dieter Niederacher; Rita K Schmutzler; Norbert Arnold
Limited relevance of the CHEK2 gene in hereditary breast cancer.
International journal of cancer. Journal international du cancer 2004;110(3):320-5.
2004: Steffen Kahlert; Ingo Bauerfeind; Alexander Strauss; Michael Untch
[Breast cancer treatment during pregnancy - experiences in the department of OB/GYN Grosshadern-Munich and review of international data].
Zentralblatt für Gynäkologie 2004;126(3):159-66.
2004: Laura Biganzoli; Michael Untch; Tomas Skacel; José-Luis Pico
Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia.
Seminars in oncology 2004;31(3 Suppl 8):27-34.
2004: Thorsten Kühn; Andreas Bembenek; H Büchels; T Decker; J Dunst; Ulrich Müllerleile; Dieter L Munz; H Ostertag; Marie-Luise Sautter-Bihl; Holger Schirrmeister; Augustinus-Harjanto Tulusan; Michael Untch; K J Winzer; C Wittekind
[Sentinel node biopsy in breast carcinoma. Interdisciplinary agreement consensus of the German Society for Serology for quality controlled application in routine clinical testing].
Der Pathologe 2004;25(3):238-43; discussion 244.
2004: Michael Untch; Holger Eidtmann; Andreas du Bois; Hans-Gerd Meerpohl; Christoph Thomssen; Andreas Ebert; Nadia Harbeck; Christian Jackisch; V Heilman; G Emons; D Wallwiener; W Wiese; Jens-Uwe Blohmer; K Höffken; Walther Kuhn; Peter Reichardt; Michael Muscholl; M Pauschinger; B Langer; Hans-Joachim Lück
Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial.
European journal of cancer (Oxford, England : 1990) 2004;40(7):988-97.
2004: Steffen Kahlert; F Von Koch; Nina Ditsch; Michael Untch
[Adjuvant treatment of breast cancer in 2004. A review of the 8th consensus conference of St. Gallen and new study results].
Gynäkologisch-geburtshilfliche Rundschau 2004;44(2):102-12.
2004: I Rühl; Ingo Bauerfeind; Steffen Kahlert; Michael Untch; Hermann Hepp
[Neoadjuvant therapy of breast cancer].
Gynäkologisch-geburtshilfliche Rundschau 2004;44(2):92-101.
2004: Ingo Bauerfeind; Isabelle Himsl; Thorsten Kühn; Michael Untch; Hermann Hepp
[Sentinel lymph node biopsy in breast cancer: state of the art].
Gynäkologisch-geburtshilfliche Rundschau 2004;44(2):84-91.
2004: Harald Sittek; M Kessler; Michael Untch; Maximilian Reiser
[Minimally invasive biopsy and preoperative marking of suspect mammary lesions].
Gynäkologisch-geburtshilfliche Rundschau 2004;44(2):69-83.
2004: B Georges; Kerstin Hermelink; Michael Untch; Hermann Hepp
[Current debate on hormone replacement therapy].
Gynäkologisch-geburtshilfliche Rundschau 2004;44(2):63-8.
2004: Andrea Vodermaier; Cornelia Caspari; Janna Köhm; Ingo Bauerfeind; Steffen Kahlert; Michael Untch
[Shared decision-making in primary breast cancer].
Zeitschrift für ärztliche Fortbildung und Qualitätssicherung 2004;98(2):127-33.
2004: Gottfried E Konecny; Y Gloria Meng; Michael Untch; He-Jing Wang; Ingo Bauerfeind; Melinda Epstein; Petra Stieber; Jean-Michel Vernes; Johnny Gutierrez; Kyu Hong; Malgorzata Beryt; Hermann Hepp; Dennis J Slamon; Mark D Pegram
Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(5):1706-16.
2004: Thorsten Kühn; Andreas Bembenek; H Büchels; T Decker; J Dunst; Ulrich Müllerleile; Dieter L Munz; H Ostertag; Marie-Luise Sautter-Bihl; Holger Schirrmeister; Augustinus-Harjanto Tulusan; Michael Untch; K J Winzer; C Wittekind
[Sentinel node biopsy in breast cancer].
Nuklearmedizin. Nuclear medicine 2004;43(1):4-9.
2003: Alexander Strauss; Katharina Middendorf; Susanne Müller-Egloff; Ivo Markus Heer; Michael Untch; Ingo Bauerfeind
[Sonographically guided percutaneous needle aspiration of breast abscesses - a minimal-invasive alternative to surgical incision].
Ultraschall in der Medizin (Stuttgart, Germany : 1980) 2003;24(6):393-8.
2003: Manfred Kaufmann; Gunter von Minckwitz; Roy Smith; Vicente Valero; Luca Gianni; Wolfgang Eiermann; Anthony Howell; Serban-Dan Costa; Philippe Beuzeboc; Michael Untch; Jens-Uwe Blohmer; Hans-Peter Sinn; Rolf Sittek; Rainer Souchon; Augustinus-Harjanto Tulusan; Tanja Volm; Hans-Jörg Senn
International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2600-8.
2003: Michael Untch; Nina Ditsch; Kerstin Hermelink
Immunotherapy: new options in breast cancer treatment.
Expert review of anticancer therapy 2003;3(3):403-8.
2003: Cornelia Caspari; Michael Untch; Andrea Vodermaier
[Shared decision making in breast cancer patients--qualitative study on mutual decision making in breast cancer in a university hospital].
Gesundheitswesen (Bundesverband der Ärzte des Öffentlichen Gesundheitsdienstes (Germany)) 2003;65(3):190-9.
2003: Reinhold Tiling; M Kessler; Michael Untch; Harald Sommer; Rainer Linke; Kirsten Brinkbäumer; Klaus Hahn
Breast cancer: monitoring response to neoadjuvant chemotherapy using Tc-99m sestamibi scintimammography.
Onkologie 2003;26(1):27-31.
2003: Gottfried E Konecny; Giovanni Pauletti; Mark D Pegram; Michael Untch; Sugandha Dandekar; Zuleima Aguilar; Cindy Wilson; Hong-Mei Rong; Ingo Bauerfeind; Margret Felber; He-Jing Wang; Malgorzata Beryt; Ram Seshadri; Hermann Hepp; Dennis J Slamon
Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
Journal of the National Cancer Institute 2003;95(2):142-53.
2003: Nina Ditsch; Barbara Mayer; Michaela Rolle; Michael Untch; Friedrich W Schildberg; Ilona Funke
Estrogen receptor expression profile of disseminated epithelial tumor cells in bone marrow of breast cancer patients.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2003;162():141-7.
2003: Petra Stieber; Rafael Molina; Daniel W Chan; Herbert A Fritsche; Ralf Beyrau; Johannes M G Bonfrer; Xavier Filella; Terrie G Gornet; Torsten Hoff; Wolfram Jäger; Gerard J van Kamp; Dorothea Nagel; Klaus Peisker; Lori J Sokoll; Frédéric Troalen; Michael Untch; Ingrid Domke
Clinical evaluation of the Elecsys CA 15-3 test in breast cancer patients.
Clinical laboratory 2003;49(1-2):15-24.
2003: Christian M Kurbacher; Ottilia M Grecu; Ursula Stier; Tobias J Gilster; Margit-M Janát; Michael Untch; Gottfried E Konecny; Howard W Bruckner; Ian Cree
ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2003;161():221-30.
2003: Michael Untch; Nina Ditsch; E Langer; Christian M Kurbacher; C Crohns; Gottfried E Konecny; Steffen Kahlert; Ingo Bauerfeind; Hermann Hepp
Chemosensitivity testing in gynecologic oncology--dream or reality?
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2003;161():146-58.
2002: Nina Ditsch; Ilona Funke; Barbara Mayer; Michael Untch
[Detection of disseminated tumor cells in bone marrow--currently of no practical therapeutic value].
MMW Fortschritte der Medizin 2002;144(41):37-9.
2002: Peter Schmid; Michael Untch; Diethelm Wallwiener; Valentin Kossé; Grigorij Bondar; Leonid Vassiljev; Valerie Tarutinov; Erika Kienle; Diana Lüftner; Kurt Possinger
Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
Anticancer research 2002;22(4):2325-32.
2002: Reinhold Tiling; Rainer Linke; M Kessler; Michael Untch; Harald Sommer; Kirsten Brinkbäumer; I Becker; Klaus Hahn
[Breast scintigraphy using 99mTc-sestamibi--use and limitations].
Nuklearmedizin. Nuclear medicine 2002;41(3):148-56.
2002: F G Ebeling; Petra Stieber; Michael Untch; Dorothea Nagel; Gottfried E Konecny; UM Schmitt; A Fateh-Moghadam; Dietrich Seidel
Serum CEA and CA 15-3 as prognostic factors in primary breast cancer.
British journal of cancer 2002;86(8):1217-22.
2002: Harald Sittek; Claudia Perlet; P Schneider; Michael Untch; T Kolopenko; Maximilian Reiser
[Stereotactic vacuum biopsy in prone and sitting position].
Der Radiologe 2002;42(1):19-24.
2001: P Stieber; Rafael Molina; Daniel W Chan; H A Fritsche; R Beyrau; Johannes M G Bonfrer; Xavier Filella; T G Gornet; Torsten Hoff; W Jäger; Gerard J van Kamp; Dorothea Nagel; K Peisker; Lori J Sokoll; Frédéric Troalen; Michael Untch; Ingrid Domke
Evaluation of the analytical and clinical performance of the Elecsys CA 15-3 immunoassay.
Clinical chemistry 2001;47(12):2162-4.
2001: Gottfried E Konecny; M Fritz; Michael Untch; A Lebeau; Margret Felber; S Lude; Malgorzata Beryt; Hermann Hepp; Dennis J Slamon; Mark D Pegram
HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer.
Breast cancer research and treatment 2001;69(1):53-63.
2001: Gottfried E Konecny; Michael Untch; J Arboleda; C Wilson; Steffen Kahlert; B Boettcher; Margret Felber; Malgorzata Beryt; S Lude; Hermann Hepp; Dennis J Slamon; Mark D Pegram
Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2448-57.
2001: Gottfried E Konecny; Michael Untch; Dennis J Slamon; Malgorzata Beryt; Steffen Kahlert; Margret Felber; E Langer; S Lude; Hermann Hepp; Mark D Pegram
Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples.
Breast cancer research and treatment 2001;67(3):223-33.
2001: Reinhold Tiling; Rainer Linke; Michael Untch; A Richter; S Fieber; Kirsten Brinkbäumer; Klaus Tatsch; Klaus Hahn
18F-FDG PET and 99mTc-sestamibi scintimammography for monitoring breast cancer response to neoadjuvant chemotherapy: a comparative study.
European journal of nuclear medicine 2001;28(6):711-20.
2001: Gottfried E Konecny; Michael Untch; A Pihan; Rainer Kimmig; Martina Gropp; Petra Stieber; Hermann Hepp; Dennis J Slamon; Mark D Pegram
Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(6):1743-9.
2001: Michael Untch; F Von Koch; C Crohns; K Sobotta; Steffen Kahlert; Gottfried E Konecny; H Hepp
Dose-dense and sequential strategies in adjuvant breast cancer therapy.
Oncology (Williston Park, N.Y.) 2001;15(5 Suppl 7):14-20.
2001: Annette Lebeau; D Deimling; C Kaltz; Andrea Sendelhofert; A Iff; B Luthardt; Michael Untch; Udo Löhrs
Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(2):354-63.
2000: Harald Sittek; E Linsmeier; Claudia Perlet; P Schneider; C Baudrexel; Michael Untch; Maximilian Reiser
[Preoperative marking and biopsy of nonpalpable breast lesions with a guidance system for the open Magnetom].
Der Radiologe 2000;40(11):1098-105.
2000: Michael Untch; F Von Koch; Steffen Kahlert; Gottfried E Konecny
Overview of epirubicin-based adjuvant therapy in breast cancer.
Clinical breast cancer 2000;1 Suppl 1():S41-5.
2000: Gottfried E Konecny; C Crohns; Mark D Pegram; Margret Felber; S Lude; Christian M Kurbacher; Ian Cree; Hermann Hepp; Michael Untch
Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Gynecologic oncology 2000;77(2):258-63.
2000: Peter Hillemanns; Michael Untch; Christian Dannecker; Reinhold Baumgartner; Herbert Stepp; Joachim Diebold; Helmut Weingandt; F Pröve; M Korell
Photodynamic therapy of vulvar intraepithelial neoplasia using 5-aminolevulinic acid.
International journal of cancer. Journal international du cancer 2000;85(5):649-53.
2000: Gottfried E Konecny; M Frank; Steffen Kahlert; Michael Untch; Hermann Hepp
[Retrospective analysis of dose intensity of epirubicin in breast cancer].
Gynäkologisch-geburtshilfliche Rundschau 2000;40(3-4):145-52.
2000: A Prechtl; Nadia Harbeck; Christoph Thomssen; C Meisner; M Braun; Michael Untch; M Wieland; BW Lisboa; T Cufer; Henner Graeff; K Selbmann; Manfred Schmitt; Fritz Jänicke
Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer.
The International journal of biological markers 2000;15(1):73-8.
1999: F C Ebeling; UM Schmitt; Michael Untch; Dorothea Nagel; A Fateh-Moghadam; Petra Stieber; Dietrich Seidel
Tumour markers CEA and CA 15-3 as Prognostic factors in breast cancer--univariate and multivariate analysis.
Anticancer research 1999;19(4A):2545-50.
1999: Peter Hillemanns; M Korell; Marcus Schmitt-Sody; Reinhold Baumgartner; Wolfgang Beyer; Rainer Kimmig; Michael Untch; Hermann Hepp
Photodynamic therapy in women with cervical intraepithelial neoplasia using topically applied 5-aminolevulinic acid.
International journal of cancer. Journal international du cancer 1999;81(1):34-8.
1999: Peter Hillemanns; Michael Untch; F Pröve; Reinhold Baumgartner; M Hillemanns; M Korell
Photodynamic therapy of vulvar lichen sclerosus with 5-aminolevulinic acid.
Obstetrics and gynecology 1999;93(1):71-4.
1998: Sascha Pahernik; Andreas Botzlar; Peter Hillemanns; Marc Dellian; M Kirschstein; Christoph Abels; M Korell; Josef Mueller-Hoecker; Michael Untch; Alwin E Goetz
Pharmacokinetics and selectivity of aminolevulinic acid-induced porphyrin synthesis in patients with cervical intra-epithelial neoplasia.
International journal of cancer. Journal international du cancer 1998;78(3):310-4.
1998: C Ritzke; Petra Stieber; Michael Untch; Dorothea Nagel; Wolfgang Eiermann; A Fateh-Moghadam
Alkaline phosphatase isoenzymes in detection and follow up of breast cancer metastases.
Anticancer research 1998;18(2B):1243-9.
1998: Harald Sittek; Claudia Perlet; Michael Untch; M Kessler; Maximilian Reiser
[Dynamic MR-mammography in invasive lobular breast cancer].
Röntgenpraxis; Zeitschrift für radiologische Technik 1998;51(7):235-42.
1998: Hans-Joachim Lück; Christoph Thomssen; Andreas du Bois; Michael Untch; BW Lisboa; G Köhler; K Diergarten
Metastatic breast cancer: experience with the combination paclitaxel plus epirubicin.
Oncology (Williston Park, N.Y.) 1998;12(1 Suppl 1):36-9.
1997: Hans-Joachim Lück; Christoph Thomssen; Andreas du Bois; Michael Untch; BW Lisboa; G Köhler; K Diergarten
Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
Seminars in oncology 1997;24(5 Suppl 17):S17-35-S17-39.
1997: Harald Sittek; Claudia Perlet; Karin Herrmann; E Linsmeier; H Kolem; Michael Untch; M Kessler; Maximilian Reiser
[MR mammography. Preoperative marking of non-palpable breast lesions with the Magnetom open at 0.2 T].
Der Radiologe 1997;37(9):685-91.
1997: Harald Sittek; M Kessler; Andreas F Heuck; T Bredl; Claudia Perlet; I Künzer; Annette Lebeau; Michael Untch; Maximilian Reiser
[Morphology and contrast enhancement of ductal carcinoma in situ in dynamic 1.0 T MR mammography].
RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin 1997;167(3):247-51.
1997: Hans-Joachim Lück; Andreas du Bois; Christoph Thomssen; BW Lisboa; Michael Untch; G Köhler; Detlef Hecker
Paclitaxel and epirubicin as first-line therapy for patients with metastatic breast cancer.
Oncology (Williston Park, N.Y.) 1997;11(4 Suppl 3):34-7.
1997: Hans-Joachim Lück; Christoph Thomssen; Andreas du Bois; BW Lisboa; Michael Untch; H Kühnle; Fritz Jänicke; Hans-Gerd Meerpohl; C Lindner; Gottfried E Konecny; Detlef Hecker; K Diergarten
Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer.
Seminars in oncology 1997;24(1 Suppl 3):S13-6.
1997: Gottfried E Konecny; Michael Untch; Hermann Hepp
[New drugs in therapy of breast carcinoma: current status and outlook].
Gynäkologisch-geburtshilfliche Rundschau 1997;37(2):54-61.
1996: Harald Sittek; M Kessler; Ulrike L Müller-Lisse; Michael Untch; H Bohmert; M Reiser
[Technics for the preoperative marking of nonpalpable breast lesions in MRT].
RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin 1996;165(1):84-7.
1996: Harald Sittek; M Kessler; Andreas F Heuck; Annette Lebeau; M Kohnert; Michael Untch; H Bohmert; M Reiser
[Dynamic MR mammography: is the course of signal intensification suitable for the differentiation of different forms of mastopathy?].
RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin 1996;165(1):59-63.
1996: Ilona Funke; S Fries; M Rolle; Markus M Heiss; Michael Untch; H Bohmert; F W Schildberg; Karl-Walter Jauch
Comparative analyses of bone marrow micrometastases in breast and gastric cancer.
International journal of cancer. Journal international du cancer 1996;65(6):755-61.
1996: H J Luck; Christoph Thomssen; A duBois; BW Lisboa; Michael Untch; H Kuhnle; Gottfried E Konecny; F Janicke; Hans-Gerd Meerpohl; C Lindner; Detlef Hecker; K Diergarten
Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
Seminars in oncology 1996;23(1 Suppl 1):33-6.
1995: Ossi R Koechli; Gabriel N Schaer; BU Sevin; J P Perras; V Schenk; M Rodriguez; Michael Untch; A Steren; U Haller
In vitro chemosensitivity of paclitaxel and other chemotherapeutic agents in malignant gestational trophoblastic neoplasms.
Anti-cancer drugs 1995;6(1):94-100.
1995: M Korell; Michael Untch; Christoph Abels; Marc Dellian; M Kirschstein; Reinhold Baumgartner; W Beyer; Alwin E Goetz
[Use of photodynamic laser therapy in gynecology].
Gynäkologisch-geburtshilfliche Rundschau 1995;35(2):90-7.
1995: Michael Untch; M Korell; M Kirschstein; Hermann Hepp
[The synergistic effect of delta-aminolevulinic acid and photodynamic laser therapy based on an in vitro model of the ATP tumor chemosensitivity test].
Gynäkologisch-geburtshilfliche Rundschau 1995;35(2):85-9.
1995: Rainer Kimmig; T Kapsner; H Spelsberg; Michael Untch; Hermann Hepp
DNA cell-cycle analysis of cervical cancer by flow cytometry using simultaneous cytokeratin labelling for identification of tumour cells.
Journal of cancer research and clinical oncology 1995;121(2):107-14.
1994: Ossi R Koechli; BU Sevin; J P Perras; Roberto Angioli; Michael Untch; A Steren; C Ramachandran; Hervy E Averette
Comparative chemosensitivity profiles in three human breast cancer cell lines with the ATP-cell viability assay.
Oncology 1994;51(6):552-8.
1994: Rainer Kimmig; H Spelsberg; T Kapsner; Michael Untch; Hermann Hepp
Flow cytometric DNA analysis of breast cancer by two colour method using cytokeratin labeling for identification of tumour cells.
Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology 1994;7(3):205-15.
1994: Michael Untch; BU Sevin; J P Perras; Roberto Angioli; A Untch; R D Hightower; Ossi R Koechli; Hervy E Averette
Evaluation of paclitaxel (taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay.
Gynecologic oncology 1994;53(1):44-9.
1994: Nadia Harbeck; Michael Untch; L Pache; W Eiermann
Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up.
British journal of cancer 1994;69(3):566-71.
1994: Michael Untch; A Untch; BU Sevin; Roberto Angioli; J P Perras; Ossi R Koechli; Hervy E Averette
Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay.
Anti-cancer drugs 1994;5(1):24-30.
1994: Michael Untch; B U Sevin
Evaluation of new drugs and combinations in gynecologic tumors and cancer cell lines with the ATP-cell viability assay.
Contributions to gynecology and obstetrics 1994;19():145-55.
1993: Ossi R Koechli; BU Sevin; J P Perras; T C Chou; Roberto Angioli; A Steren; Michael Untch; Hervy E Averette
Characteristics of the combination paclitaxel plus doxorubicin in breast cancer cell lines analyzed with the ATP-cell viability assay.
Breast cancer research and treatment 1993;28(1):21-7.
1993: Roberto Angioli; BU Sevin; J P Perras; Michael Untch; Ossi R Koechli; H N Nguyen; A Steren; J G Schwade; C Villani; Hervy E Averette
In vitro potentiation of radiation cytotoxicity by recombinant interferons in cervical cancer cell lines.
Cancer 1993;71(11):3717-25.
1993: Roberto Angioli; Michael Untch; BU Sevin; A Steren; R D Hightower; J P Perras; H N Nguyen; Ossi R Koechli; Hervy E Averette
Enhancement of progesterone receptor levels by interferons in AE-7 endometrial cancer cells.
Cancer 1993;71(9):2776-81.
1993: R D Hightower; BU Sevin; J Perras; H Nguyen; Roberto Angioli; Michael Untch; Hervy E Averette
In vitro evaluation of the novel chemotherapeutic agents U-73,975, U-77,779, and U-80,244 in gynecologic cancer cell lines.
Cancer investigation 1993;11(3):276-82.
1993: Michael Untch; C Nestle-Krämling; Gottfried E Konecny; Nadia Harbeck; Ilona Funke; Rainer Kimmig; Hermann Hepp
[Prognostic value of tumor cells in bone marrow in breast cancer].
Gynäkologisch-geburtshilfliche Rundschau 1993;33 Suppl 1():308-10.
1993: Rainer Kimmig; Michael Untch; D Pfeiffer; D Egner; Thomas Strowitzki; Hermann Hepp
[Multiparametric flow cytometry determination of the EGF receptor and DNA cell cycle distribution in cervix cancer].
Gynäkologisch-geburtshilfliche Rundschau 1993;33 Suppl 1():283-4.
1993: Michael Untch; BU Sevin; A Untch; Gottfried E Konecny; C Nestle-Krämling; M Korell; Hermann Hepp
[Testing chemosensitivity of cancer cell lines and gynecologic tumors with the ATP assay].
Gynäkologisch-geburtshilfliche Rundschau 1993;33 Suppl 1():311-3.
1993: Gottfried E Konecny; C Nestle-Krämling; Michael Untch
[Use of G-CSF in dose-intensified chemotherapy of breast cancer with FEC (500/75/500 mg/m2 KO) in the adjuvant and metastatic situation].
Gynäkologisch-geburtshilfliche Rundschau 1993;33 Suppl 1():301-2.
1992: R D Hightower; BU Sevin; J P Perras; Michael Untch; Roberto Angioli; R Ramos; Hervy E Averette
Comparison of U-73,975 and cisplatin cytotoxicity in fresh cervical and ovarian carcinoma specimens with the ATP-chemosensitivity assay.
Gynecologic oncology 1992;47(2):186-90.
1992: Michael Untch; BU Sevin; J P Perras; Roberto Angioli; A Baibl; H N Nguyen; R D Hightower; Hervy E Averette
Chemosensitivity to the new anthracycline pirarubicin and other chemotherapeutic agents in primary and recurrent ovarian tumors in vitro.
Gynecologic oncology 1992;47(2):172-8.
1992: H N Nguyen; BU Sevin; Hervy E Averette; J Perras; Michael Untch; R Ramos; D Donato; Manuel Penalver
Comparative evaluation of pirarubicin and adriamycin in gynecologic cancer cell lines.
Gynecologic oncology 1992;45(2):164-73.
1992: Roberto Angioli; BU Sevin; J P Perras; Michael Untch; R D Hightower; H N Nguyen; A Steren; C Villani; Hervy E Averette
Rationale of combining radiation and interferon for the treatment of cervical cancer.
Oncology 1992;49(6):445-9.
1990: W Eiermann; Nadia Harbeck; Michael Untch
[Possibilities in immunocytochemistry exemplified by bone marrow aspiration cytology in patients with breast carcinoma].
Der Gynäkologe 1990;23(6):358-64.